Skip to content
#gene editing Open access

Dynamic reprogramming and A-to-I RNA editing in neutrophils in response to tumor induction.

Sep 2026 · Journal of Biological Chemistry · pp. 113569 · 0 citations
Medicine

TL;DR

Results indicate a possible link between transcriptional remodeling, RNA editing, and functional polarization of HCC-induced neutrophils, and provide an exploratory framework for investigating ADAR-regulated RNA editing in tumor-immune communication.

Abstract

Tumor-associated neutrophils (TANs) play dual roles in cancer progression, yet the molecular basis of their reprogramming by tumor cells remains poorly understood. Here, we performed a time-resolved transcriptomic and RNA editome analysis of neutrophils co-cultured with three hepatocellular carcinoma (HCC) cell lines using 293T cells as control. We observed consistent transcriptional remodeling across treatments, with progressive upregulation of pro-tumor genes and downregulation of anti-tumor genes, which were associated with functions of neutrophil chemotaxis, NETosis, metabolic reprogramming, and N1-to-N2 polarization. Concurrently, global A-to-I RNA editing, ADAR expression, together with ADAR1-MDA5-immunity and ADAR2-recoding axes were markedly reduced in HCC-induced neutrophils, compatible with the tumor-driven reprogramming hypothesis. Differential editing analysis revealed three key downregulated recoding sites with distinct evolutionary histories, MED21 (p.Gln145Arg), HSPA1L (p.Asn153Asp), and ZNF397 (p.Tyr481Cys), which may alter transcriptional and stress-regulatory functions of downstream targets. Together, these results indicate a possible link between transcriptional remodeling, RNA editing, and functional polarization of HCC-induced neutrophils. Since our analyses are in silico, the proposed mechanistic links should be interpreted as hypotheses for future validation. Our findings provide an exploratory framework for investigating ADAR-regulated RNA editing in tumor-immune communication.

Read PDF

Similar papers

#gene editing Open access Oct 2026

CRISPR–Cas9 Editing of Myeloid Lectins Reveals Target-Dependent Transcriptional Remodeling in Tumor-Associated Macrophages

Tumor-associated macrophages (TAMs) integrate multiple microenvironmental signals, including lectin-mediated recognition of tumor-associated glycans. Although several myeloid lectins have been implicated in tumor–macrophage interactions, their contributions to immunosuppressive TAM phenotypes remain poorly defined. We...

Gonçalo Trindade, M. Pinto, G. Domenici et al. · 0 citations
Open access Aug 2026

Single-cell profiling identifies STAT3/NF-κB regulatory hubs and cytokine crosstalk in the tumor microenvironment

Integrative single-cell RNA sequencing analysis of publicly available datasets from non-small cell lung cancer and breast cancer is performed to systematically map transcriptional heterogeneity and regulatory networks within the TME, providing a systems-level framework of TME organization.

M. O. Odubote, Chiemeka Elochi Emeribe · 0 citations
Review Open access Sep 2026

ADAR1 promotes cancer fitness by buffering endogenous RNA sensing.

Tumors exploit multifaceted strategies to survive and avoid destruction by the immune system. The RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) regulates double-stranded (ds)RNA metabolism by catalyzing the adenosine-to-inosine (A-to-I) change, which is one of the most prevalent RNA modifications in ma...

C. Cerboni, Stefano Petrai, M. Greco et al. · 0 citations
Review Aug 2026

RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting

It is argued that while epitranscriptomics represents a compelling regulatory axis in cancer cell death, advancing the field will require integrative, high-resolution, and functionally precise approaches to move beyond correlative frameworks toward mechanistic and clinically actionable insights.

A. Mukherjee, Ankit Kumar Bharti, D. Mathew et al. · 0 citations
Oct 2026

Single-cell transcriptome analysis reveals onco-fetal reprogramming with implications for drug resistance and clinical outcome.

Onco-fetal reprogramming of the tumor ecosystem induces fetal-like characteristics, leading to tumor growth and malignant progression. Here, we develop a robust computational pipeline to systematically identify onco-fetal (OF) cells, using single-cell transcriptomic data from corresponding fetal and tumor tissues acros...

Yong-Le Xu, Shao-Yi Chen, Zheng-Lin Lu et al. · 0 citations
Open access Sep 2026

CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity

A candidate-based CRISPR activation (CRISPRa) functional screen is developed to identify regulators of conventional dendritic cell (cDC)-fate specification and concludes that the transcription factors Zfp366/Znf366, Pu.1, Irf8, and Batf3 (ZPIB) are sufficient to convert GBM cells into cDC-like cells.

Xiao Liu, Mao-Rong Zhu, Cheng Zou et al. · 0 citations

Related blog posts

Microsoft Research Blog Nov 5, 2026

Formally verifying agent-written full-stack web apps with PDD Kit

AI agents can generate code at a scale that’s hard for humans to review line-by-line. PDD Kit helps ensure the code is doing what the developer intended by creating formal specifications and testing against them. It converts developer intent into a Verus specification, proves AI-generated code meets it for every input, and uses tests where proofs aren't practical. Developers review intent, not every line. The post Formally verifying agent-written full-stack web apps with PDD Kit appeared first o…

Microsoft Research Blog Oct 29, 2026

Microsoft Research Focus – Edition #97

Host Sowbhagya Suresh shares some of the latest news and cutting-edge research from across Microsoft—from understanding the challenges facing coding agents to uncovering how people use AI at work and improving extended-range weather forecasting. The post Microsoft Research Focus – Edition #97 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.